Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.52 |
| ▸ | OPRD1 | P41143 | 12/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.51 |
| ▸ | CCKAR | P32238 | 3/20 | 0.51 |
| ▸ | CCKBR | P32239 | 3/20 | 0.51 |
| ▸ | APC | P25054 | 3/20 | 0.49 |
| ▸ | ENPEP | Q07075 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30584641 | 0.89 | OPRD1 (0.55) | NAALAD2OPRD1OPRM1OPRK1CCKAR | |
| SCHEMBL30495745 | 0.89 | OPRD1 (0.49) | OPRD1OPRM1OPRK1CCKARCCKBR | |
| SCHEMBL29816684 | 0.89 | NAALAD2 (0.54) | NAALAD2OPRD1OPRM1OPRK1CCKAR | |
| SCHEMBL31684377 | 0.88 | NAALAD2 (0.65) | NAALAD2OPRM1ENPEP | |
| SCHEMBL30584647 | 0.88 | OPRD1 (0.53) | NAALAD2OPRD1OPRM1OPRK1CCKAR | |
| SCHEMBL29379340 | 0.87 | NAALAD2 (0.59) | NAALAD2OPRD1OPRM1OPRK1CCKAR | |
| SCHEMBL29695521 | 0.87 | BACE1 (0.52) | NAALAD2OPRD1OPRM1OPRK1 | |
| SCHEMBL29630516 | 0.87 | OPRD1 (0.52) | NAALAD2OPRD1OPRM1OPRK1APC | |
| SCHEMBL31031510 | 0.87 | OPRD1 (0.61) | OPRD1OPRM1OPRK1CCKARCCKBR | |
| SCHEMBL29735690 | 0.87 | NAALAD2 (0.56) | NAALAD2OPRD1OPRM1OPRK1CCKAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4267193-A1 | IMPROVED CD30 TARGETING ANTIBODY DRUG CONJUGATES AND USES THEREOF | Ludwig-Maximilians-Universität München (DE) | 2023-11-01 | — | — | EP | disclosed |
| WO-2022136555-A9 | IMPROVED CD30 TARGETING ANTIBODY DRUG CONJUGATES AND USES THEREOF | LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN (DE) | 2022-09-22 | — | — | WO | disclosed |
| WO-2022136555-A1 | IMPROVED CD30 TARGETING ANTIBODY DRUG CONJUGATES AND USES THEREOF | LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN (DE) | 2022-06-30 | — | — | WO | disclosed |
| US-20220193251-A1 | CD30 TARGETING ANTIBODY DRUG CONJUGATES AND USES THEREOF | LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN (DE) | 2022-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220193251-A1 | CD30 TARGETING ANTIBODY DRUG CONJUGATES AND USES THEREOF | TUBB6, GALNT10, TUBB | NAALAD2 219/4885OPRD1 4213/4885OPRM1 3989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.